title: alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis.
abstract: Five patients with Alzheimer's disease and five healthy volunteers were examined by SPECT with the nicotinic receptor ligand 123I-5-IA-85380. Patients were scanned before and after 6 weeks of treatment with donepezil. Quantification by regions of interest was reliable and the optimal normalisation procedure used cerebellar ratios. We found relative reductions in 5-IA binding capacity in patients in thalamus, frontal and central regions of interest of approximately one standard deviation unit (Cohen's d = 1). Reductions in binding after treatment with the acetylcholinesterase inhibitor donepezil of the same magnitude occurred in the brain stem. The study was clearly too small to confirm group differences, but it suggests that 5-IA can be used to examine both group differences and treatment effects in patients with Alzheimer's disease.
authors.affiliation: Division of Psychiatry, University of Edinburgh, Edinburgh, UK.
authors.forename: Emma
authors.initials: E
authors.lastname: Terrière
authors.forename: Mike
authors.initials: M
authors.lastname: Sharman
authors.forename: Claire
authors.initials: C
authors.lastname: Donaghey
authors.forename: Lucie
authors.initials: L
authors.lastname: Herrmann
authors.forename: Jane
authors.initials: J
authors.lastname: Lonie
authors.forename: Marion
authors.initials: M
authors.lastname: Strachan
authors.forename: Nadine
authors.initials: N
authors.lastname: Dougall
authors.forename: Jonathan
authors.initials: J
authors.lastname: Best
authors.forename: Klaus P
authors.initials: KP
authors.lastname: Ebmeier
authors.forename: Sally
authors.initials: S
authors.lastname: Pimlott
authors.forename: Jim
authors.initials: J
authors.lastname: Patterson
authors.forename: David
authors.initials: D
authors.lastname: Wyper
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000523:psychology; D001384:Azetidines / Q000138:chemical synthesis; D001921:Brain / Q000000981:diagnostic imaging; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D000077265:Donepezil; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007189:Indans / Q000627:therapeutic use; D008297:Male; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use; D015588:Observer Variation; D010865:Pilot Projects; D010880:Piperidines / Q000627:therapeutic use; D011725:Pyridines / Q000138:chemical synthesis; D019275:Radiopharmaceuticals / Q000138:chemical synthesis; D011978:Receptors, Nicotinic / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: C426745:5-iodo-3-(2-azetidinylmethoxy)pyridine; D001384:Azetidines; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D011725:Pyridines; D019275:Radiopharmaceuticals; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; D000077265:Donepezil